EA201390827A1 - Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом - Google Patents
Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозомInfo
- Publication number
- EA201390827A1 EA201390827A1 EA201390827A EA201390827A EA201390827A1 EA 201390827 A1 EA201390827 A1 EA 201390827A1 EA 201390827 A EA201390827 A EA 201390827A EA 201390827 A EA201390827 A EA 201390827A EA 201390827 A1 EA201390827 A1 EA 201390827A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- improve
- multiple sclerosis
- lakininimode
- patients
- life
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000006866 deterioration Effects 0.000 abstract 2
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 abstract 2
- 229960004577 laquinimod Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010016256 fatigue Diseases 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42074210P | 2010-12-07 | 2010-12-07 | |
| US201161542996P | 2011-10-04 | 2011-10-04 | |
| PCT/US2011/063460 WO2012078591A1 (en) | 2010-12-07 | 2011-12-06 | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201390827A1 true EA201390827A1 (ru) | 2013-12-30 |
Family
ID=46162796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201390827A EA201390827A1 (ru) | 2010-12-07 | 2011-12-06 | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20120142730A1 (https=) |
| EP (1) | EP2648732A4 (https=) |
| JP (2) | JP2013544887A (https=) |
| KR (1) | KR20130124518A (https=) |
| CN (1) | CN103260624B (https=) |
| AU (2) | AU2011338647A1 (https=) |
| BR (1) | BR112013014061A2 (https=) |
| CA (1) | CA2820586A1 (https=) |
| CL (1) | CL2013001602A1 (https=) |
| EA (1) | EA201390827A1 (https=) |
| IL (1) | IL250726A0 (https=) |
| MX (1) | MX2013006464A (https=) |
| NZ (1) | NZ611628A (https=) |
| PE (1) | PE20140872A1 (https=) |
| PH (1) | PH12013501193A1 (https=) |
| SG (2) | SG190449A1 (https=) |
| UA (1) | UA111959C2 (https=) |
| WO (1) | WO2012078591A1 (https=) |
| ZA (1) | ZA201304237B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
| PT2467372T (pt) | 2009-08-10 | 2016-08-23 | Teva Pharma | Tratamento de distúrbios relacionados com bdnf usando laquinimod |
| JP5819328B2 (ja) * | 2010-03-03 | 2015-11-24 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療 |
| CN102791130B (zh) * | 2010-03-03 | 2015-02-25 | 泰华制药工业有限公司 | 使用拉喹莫德治疗狼疮肾炎 |
| SG10201505236YA (en) | 2010-07-09 | 2015-08-28 | Teva Pharma | Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| HK1198296A1 (en) | 2012-02-16 | 2015-03-27 | Teva Pharmaceutical Industries Ltd. | N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| HK1211525A1 (en) * | 2012-09-27 | 2016-05-27 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| US20140107154A1 (en) * | 2012-10-12 | 2014-04-17 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for reducing thalamic damage in multiple sclerosis |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| EA201591507A1 (ru) * | 2013-02-15 | 2015-12-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение рассеянного склероза лахинимодом |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| HK1220125A1 (zh) | 2013-03-14 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德的透皮配方 |
| TW201609098A (zh) * | 2013-12-20 | 2016-03-16 | 泰瓦藥品工業有限公司 | 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途 |
| WO2015109083A1 (en) * | 2014-01-17 | 2015-07-23 | Teva Pharmaceutical Industries Ltd. | Treatment of crohn's disease using low doses of laquinimod |
| EA201692180A1 (ru) * | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| CN114699409A (zh) * | 2014-10-16 | 2022-07-05 | 诺华股份有限公司 | 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合 |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP3863628B1 (en) * | 2018-10-09 | 2023-12-27 | MediciNova, Inc. | Combination of ibudilast and interferon-beta and methods of using same |
| AU2020316640A1 (en) * | 2019-07-22 | 2022-03-03 | Actelion Pharmaceuticals Ltd | Methods of treating multiple sclerosis |
| CN110688373A (zh) * | 2019-09-17 | 2020-01-14 | 杭州绿度信息技术有限公司 | 一种基于逻辑回归的offset方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006029411A2 (en) * | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US20060205822A1 (en) * | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| EP2680006A1 (en) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Treatment for Amyotrophic Lateral Sclerosis |
| RS54328B1 (sr) * | 2009-06-19 | 2016-02-29 | Teva Pharmaceutical Industries Ltd. | Tretman multiple skleroze lakvinimodom |
-
2011
- 2011-12-06 WO PCT/US2011/063460 patent/WO2012078591A1/en not_active Ceased
- 2011-12-06 SG SG2013042403A patent/SG190449A1/en unknown
- 2011-12-06 JP JP2013543255A patent/JP2013544887A/ja active Pending
- 2011-12-06 PE PE2013001357A patent/PE20140872A1/es not_active Application Discontinuation
- 2011-12-06 UA UAA201308448A patent/UA111959C2/uk unknown
- 2011-12-06 KR KR1020137017362A patent/KR20130124518A/ko not_active Ceased
- 2011-12-06 AU AU2011338647A patent/AU2011338647A1/en not_active Abandoned
- 2011-12-06 CA CA2820586A patent/CA2820586A1/en not_active Abandoned
- 2011-12-06 SG SG10201509831XA patent/SG10201509831XA/en unknown
- 2011-12-06 EA EA201390827A patent/EA201390827A1/ru unknown
- 2011-12-06 PH PH1/2013/501193A patent/PH12013501193A1/en unknown
- 2011-12-06 NZ NZ611628A patent/NZ611628A/en not_active IP Right Cessation
- 2011-12-06 EP EP11846599.6A patent/EP2648732A4/en not_active Withdrawn
- 2011-12-06 US US13/312,284 patent/US20120142730A1/en not_active Abandoned
- 2011-12-06 MX MX2013006464A patent/MX2013006464A/es unknown
- 2011-12-06 CN CN201180060414.8A patent/CN103260624B/zh not_active Expired - Fee Related
- 2011-12-06 BR BR112013014061A patent/BR112013014061A2/pt not_active Application Discontinuation
-
2013
- 2013-06-05 CL CL2013001602A patent/CL2013001602A1/es unknown
- 2013-06-10 ZA ZA2013/04237A patent/ZA201304237B/en unknown
-
2016
- 2016-12-26 JP JP2016251360A patent/JP2017095476A/ja active Pending
-
2017
- 2017-02-22 IL IL250726A patent/IL250726A0/en unknown
- 2017-03-28 AU AU2017202055A patent/AU2017202055A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ611628A (en) | 2015-06-26 |
| JP2017095476A (ja) | 2017-06-01 |
| WO2012078591A1 (en) | 2012-06-14 |
| CA2820586A1 (en) | 2012-06-14 |
| SG10201509831XA (en) | 2015-12-30 |
| SG190449A1 (en) | 2013-07-31 |
| CN103260624B (zh) | 2015-06-03 |
| ZA201304237B (en) | 2014-08-27 |
| PH12013501193A1 (en) | 2013-07-15 |
| WO2012078591A8 (en) | 2012-08-02 |
| CL2013001602A1 (es) | 2013-10-25 |
| AU2011338647A8 (en) | 2013-09-05 |
| UA111959C2 (uk) | 2016-07-11 |
| AU2017202055A1 (en) | 2017-04-20 |
| KR20130124518A (ko) | 2013-11-14 |
| EP2648732A4 (en) | 2014-04-30 |
| MX2013006464A (es) | 2013-07-29 |
| PE20140872A1 (es) | 2014-08-09 |
| AU2011338647A1 (en) | 2013-07-04 |
| CN103260624A (zh) | 2013-08-21 |
| JP2013544887A (ja) | 2013-12-19 |
| IL250726A0 (en) | 2017-04-30 |
| BR112013014061A2 (pt) | 2016-09-13 |
| US20120142730A1 (en) | 2012-06-07 |
| EP2648732A1 (en) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| MX2011013902A (es) | Tratamiento de esclerosis multiple con laquinimod. | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| SG176628A1 (en) | Aminopyrrolidinone derivatives and uses thereof | |
| NZ589445A (en) | Rasagiline for parkinson's disease modification | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| MY175997A (en) | Antl-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| UA98136C2 (ru) | Применение аклидиния для лечения респираторных заболеваний | |
| MX2012007813A (es) | Tratamiento del sindrome de apnea obstructiva del sueño con una combinacion de un hinibidor de anhidrasa carbonica y un agente activo adicional. | |
| PH12014500381A1 (en) | Therapeutic methods | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| EA201301168A1 (ru) | Аклидиний для применения при улучшении качества сна у пациентов с респираторными заболеваниями | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist | |
| NZ597675A (en) | Medicament for the long term nsaid use | |
| CY1119845T1 (el) | Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος | |
| EA201070844A1 (ru) | ((e)-n-{3-[1-(8-фтор-11h-10-окса-1-аза-дибензо[a,d]циклогептен-5-илиден)пропил]фенил}метансульфонамид) в качестве модулятора рецепторов глюкокортикоидов для лечения ревматизма | |
| RU2008107113A (ru) | Средство и способ профилактики и лечения пациентов с болезнью альцгеймера |